Clinical Trials Logo

Filter by:
NCT ID: NCT05098327 Withdrawn - Prostate Cancer Clinical Trials

Pioglitazone and Insulin Resistance in ADT

Start date: August 1, 2021
Phase: Phase 3
Study type: Interventional

This study is being done to establish the mechanisms underlying insulin resistance (reduced insulin action that can lead to high blood sugar and maybe diabetes) in patients undergoing androgen deprivation therapy (ADT) for prostate carcinoma as well as to investigate the role of pioglitazone therapy in reduction/ reversal of that insulin resistance

NCT ID: NCT05098145 Withdrawn - Clinical trials for Diffuse Cutaneous Systemic Sclerosis

A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis

FREEDOM-3
Start date: November 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label study to evaluate the safety and tolerability and explore the efficacy of FCR001 cell therapy in adults with rapidly progressive Diffuse Cutaneous Systemic Sclerosis (dcSSc) at risk for organ failure.

NCT ID: NCT05097729 Withdrawn - Chronic Pain Clinical Trials

rTMS for Relieving Chronic OA Pain

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

In this study the investigators aim to examine the effects of Transcranial Magnetic Stimulation (TMS) on hippocampal network connectivity and pain levels in individuals with pain due to knee osteoarthritis.

NCT ID: NCT05097651 Withdrawn - Sleep Disturbance Clinical Trials

CBD for Sleep in People With HIV

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

This study will obtain preliminary information about whether, and at what dose, cannabidiol (CBD) may help with insomnia in people living with human immunodeficiency virus (HIV). The study will be a 5-week randomized, double-blind placebo-controlled phase II trial using daily oral CBD doses between 50mg and 600mg. Sleep problems will be measured using a wrist-worn device and by self-report. Performance on tests of thinking skills will be compared before and after CBD/placebo treatment. Positive study results will provide support for the use of CBD as a potential treatment for insomnia.

NCT ID: NCT05097040 Withdrawn - Stroke Clinical Trials

A Coach-Guided Online Acceptance and Commitment Therapy (ACT) Intervention for Stroke Survivors

Start date: January 9, 2022
Phase: N/A
Study type: Interventional

The pilot randomized controlled trial aims to assess effects of a guided online acceptance and commitment therapy (ACT) intervention on distressed stroke survivors compared to the care-as-usual control group. A total of 24 stroke survivors who meet the inclusion criteria will be recruited and randomized to either the intervention group or the control group. Exploratory hypotheses are that the ACT group will show improvements in mental health outcomes (e.g., depressive symptoms, anxiety, and stress), and ACT processes (e.g., psychological flexibility/acceptance) at posttest and 2-month follow-up, compared to the care-as-usual control group. Also, the project will evaluate the feasibility of recruitment, adherence, and retention of participants and explore participants' experiences in the ACT intervention through semi-structured interviews at posttest.

NCT ID: NCT05093894 Withdrawn - Ventral Hernia Clinical Trials

Microlyte in Prevention of SSI After Open Ventral Hernia Repair

Start date: December 14, 2021
Phase: N/A
Study type: Interventional

Participants who are scheduled to have open ventral hernia repair (OVHR) will be asked to take part in this study. The purpose of this study is to find out if placing Microlyte (which is a dissolvable sheet coated in silver) on the surgical incision is better than placing nothing on the surgical incision when it comes to decreasing the chance of surgical site infections. The study device has been cleared by the Food and Drug Administration (FDA) for use on surgical incisions. A total of 280 participants will be included in the study. Participation will last for about 90 days.

NCT ID: NCT05093868 Withdrawn - Clinical trials for Persistent Atrial Fibrillation

Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF)

Start date: September 2, 2022
Phase: N/A
Study type: Interventional

This is a prospective, observational, single center pilot trial to find out if a new computerized technology for analysis of the electrical activity recorded during atrial fibrillation can identify the electrical source of this arrhythmia. If we are able to reliably identify the source, then in the future we may be able to use this technology to determine the optimal sites for catheter ablation of atrial fibrillation in the heart. The present study will compare the standard electrical recordings to the new computerized algorithm analysis of recordings gathered at the same time. The study will enroll 30 participants with persistent or longstanding persistent atrial fibrillation (AF) that are scheduled for elective catheter ablation of AF. The catheters that are being placed in the heart are standard Food and Drug Administration (FDA)-approved mapping catheters. The investigational computerized software that will be employed in the trial will be used after the case has done and will not directly impact any of the activities during the ablation procedure. Information learned from this trial will improve understanding of the mechanisms of atrial fibrillation and will potentially improve success rates of AF ablation for patients in the future and will be used to design a prospective trial.

NCT ID: NCT05093387 Withdrawn - Clinical trials for Anatomic Stage IV Breast Cancer AJCC v8

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Start date: November 10, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial studies the effect of SGT-53, carboplatin, and pembrolizumab in treating patients with triple negative inflammatory breast that has spread to other parts of the body (metastatic). SGT-53 is a gene therapy that changes the deoxyribonucleic acid (DNA) of patients' tumor cells to make it easier for the immune system to recognize them. SGT-53 targets the TP53 gene, which is frequently mutated in IBC cells. Chemotherapy drugs, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SGT-53, pembrolizumab, and carboplatin may help the control the disease in patients with triple negative inflammatory breast cancer.

NCT ID: NCT05087914 Withdrawn - Acute Pain Clinical Trials

Novel Non-opioid Post-surgical Pain Treatment in Females

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

This study aims to determine if treatment with Carbidopa/Levodopa and Naproxen in females (biological sex) with acute pain after a bunionectomy or toe fusion (24hrs, 48hrs and 5 days) will reduce pain when compared with females receiving Placebo and Naproxen.

NCT ID: NCT05085379 Withdrawn - Middle Ear Disease Clinical Trials

Optical Coherence Tomography of the Middle Ear Using Ossiview

Start date: November 2, 2023
Phase:
Study type: Observational

The aim of this study is to understand the diagnostic applications for this imaging technology and identify particular disorders to target for future clinical investigations. Images obtained with the Ossiview device will be correlated to other standard of care (SoC) testing including microscopic otoscopy, CT scans, MRIs, audiologic testing results, and surgical and pathology reports.